Elotuzumab (HuLuc63)
by Jessica Langholtz
Updated: Dec 3, 2009
Updated: Dec 3, 2009
| Brand Name: | |
| Generic Name: | elotuzumab |
| Code Name: | HuLuc63 |
| Company: | Facet Biotech/Bristol-Myers Squibb |
| FDA Clinical Phase: | 1/2 |
Description:
Elotuzumab (news), a monoclonal antibody, selectively targets glycoproteins that are highly expressed on myeloma cells but not on healthy cells. In the presence of elotuzumab, myeloma cells undergo cell lysis and death. Clinical trials are currently underway to examine the activity of elotuzumab in patients with refractory or relapsed myeloma.
Clinical Trials:
For a list of clinical trials studying elotuzumab for the treatment of multiple myeloma, see ClinicalTrials.gov.
Web site for elotuzumab: http://www.facetbiotech.com/pipeline/product/elotuzumab/
Related Articles:
- Getting To Know: TNB-383B
- Getting To Know: Tiragolumab
- bb2121 Continues To Impress As Potential New Multiple Myeloma Therapy (ASCO 2018)
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma
- Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2018)
